Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66075-1-Ig - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#66075-1-Ig, RRID:AB_11182595
- Product name
- PMS2 antibody
- Antibody type
- Monoclonal
- Description
- PMS2 antibody (Cat. #66075-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, rat, mouse and has been validated for the following applications: WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 1G4E6
- Vial size
- 20ul, 150ul
Submitted references Intercellular adhesion molecule-1 suppresses TMZ chemosensitivity in acquired TMZ-resistant gliomas by increasing assembly of ABCB1 on the membrane.
MRE11A: a novel negative regulator of human DNA mismatch repair.
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer.
Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence.
Remodeling Chondroitin-6-Sulfate-Mediated Immune Exclusion Enhances Anti-PD-1 Response in Colorectal Cancer with Microsatellite Stability.
Sebaceous adenoma occurring within an intracranial dermoid cyst.
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Mismatch repair deficiency in canine neoplasms.
Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Zhang X, Tan Y, Li T, Tan D, Fu B, Yang M, Chen Y, Cao M, Xuan C, Du Q, Hu R, Wang Q
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2024 Sep;76:101112
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2024 Sep;76:101112
MRE11A: a novel negative regulator of human DNA mismatch repair.
Du D, Yang Y, Zhang Y, Wang G, Chen L, Guan X, Rasmussen LJ, Liu D
Cellular & molecular biology letters 2024 Mar 14;29(1):37
Cellular & molecular biology letters 2024 Mar 14;29(1):37
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer.
Jiang Y, Wang Y, Chen G, Sun F, Wu Q, Huang Q, Zeng D, Qiu W, Wang J, Yao Z, Liang B, Li S, Wu J, Huang N, Wang Y, Chen J, Zhai X, Huang L, Xu B, Yamamoto M, Tsukamoto T, Nomura S, Liao W, Shi M
Cell metabolism 2024 Aug 6;36(8):1806-1822.e11
Cell metabolism 2024 Aug 6;36(8):1806-1822.e11
Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence.
Ran X, Hu T, Li Z
Frontiers in oncology 2022;12:810631
Frontiers in oncology 2022;12:810631
Remodeling Chondroitin-6-Sulfate-Mediated Immune Exclusion Enhances Anti-PD-1 Response in Colorectal Cancer with Microsatellite Stability.
Wu Q, Huang Q, Jiang Y, Sun F, Liang B, Wang J, Hu X, Sun M, Ma Z, Shi Y, Liang Y, Tan Y, Zeng D, Yao F, Xu X, Yao Z, Li S, Rong X, Huang N, Sun L, Liao W, Shi M
Cancer immunology research 2022 Feb;10(2):182-199
Cancer immunology research 2022 Feb;10(2):182-199
Sebaceous adenoma occurring within an intracranial dermoid cyst.
Minamisaka T, Imura J, Shiraishi K, Takagi K, Tomia T, Tanaka S, Noguchi A, Akai T, Noguchi K, Kuroda S
Neuropathology : official journal of the Japanese Society of Neuropathology 2022 Aug;42(4):289-294
Neuropathology : official journal of the Japanese Society of Neuropathology 2022 Aug;42(4):289-294
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S, Sule A, Sundaram RK, Bindra RS
Scientific reports 2022 Apr 6;12(1):5827
Scientific reports 2022 Apr 6;12(1):5827
Mismatch repair deficiency in canine neoplasms.
Inanaga S, Igase M, Sakai Y, Tanabe M, Shimonohara N, Itamoto K, Nakaichi M, Mizuno T
Veterinary pathology 2021 Nov;58(6):1058-1063
Veterinary pathology 2021 Nov;58(6):1058-1063
Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J, Ke G, Bi R, Wu X
Journal of surgical oncology 2020 Sep;122(3):538-546
Journal of surgical oncology 2020 Sep;122(3):538-546
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.
Guo X, Wu W, Gao H, Li X, He Q, Zhu Y, Liu N
Molecular genetics & genomic medicine 2019 Jun;7(6):e721
Molecular genetics & genomic medicine 2019 Jun;7(6):e721
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Liang D, Shi S, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X
Surgery 2018 May;163(5):1080-1089
Surgery 2018 May;163(5):1080-1089
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The PMS2 antibody from Proteintech is a mouse monoclonal antibody to a fusion protein of human PMS2. This antibody recognizes human antigen. The PMS2 antibody has been validated for the following applications: ELISA, WB analysis.
